Neurotech International Ltd has released a press release.
Approval received for NTI164 Phase 3 Clinical Study in ASD
Earlier from Neurotech International
- Quarterly Activities/Appendix 4C Cash Flow Report
- Binding Commitments Received for a $4 Million Placement
- Trading Halt